BACKGROUND: The concept of an altered collective gut microbiota rather than identification of a single culprit is possibly the most significant development in inflammatory bowel disease research. We have entered the "omics" era, which now allows us to undertake large-scale/high-throughput microbiota analysis which may well define how we approach diagnosis and treatment of inflammatory bowel disease (IBD) in the future, with a strong steer towards personalised therapeutics.
AIM: To assess current epidemiological, experimental and clinical evidence of the current status of knowledge relating to the gut microbiome, and its role in IBD, with emphasis on reviewing the evidence relating to microbial therapeutics and future microbiome modulating therapeutics.
METHODS: A Medline search including items 'intestinal microbiota/microbiome', 'inflammatory bowel disease', 'ulcerative colitis', 'Crohn's disease', 'faecal microbial transplantation', 'dietary manipulation' was performed.
RESULTS: Disease remission and relapse are associated with microbial changes in both mucosal and luminal samples. In particular, a loss of species richness in Crohn's disease has been widely observed. Existing therapeutic approaches broadly fall into 3 categories, namely: accession, reduction or indirect modulation of the microbiome. In terms of microbial therapeutics, faecal microbial transplantation appears to hold the most promise; however, differences in study design/methodology mean it is currently challenging to elegantly translate results into clinical practice.
CONCLUSIONS: Existing approaches to modulate the gut microbiome are relatively unrefined. Looking forward, the future of microbiome-modulating therapeutics looks bright with several novel strategies/technologies on the horizon. Taken collectively, it is clear that ignoring the microbiome in IBD is not an option.
Bibliographical noteACKNOWLEDGEMENT: Declaration of personal interests: JM has received personal fees, consultancy fees and other from EnteroBiotix Limited, Biotechspert Limited and EuroBiotix CIC. GI has received speaker's fees and/or consultancy fees from: Biocure, FarTo, IBSA, Malesci, Sanofi. IM: None. RH has received speaker's fees, conference support or consultancy fees from Nutricia, Dr Falk, MSD Immunology and 4D Pharma. He is supported by a Career Researcher Fellowship from NHS Research Scotland. The Glasgow paediatric IBD team is supported by the Catherine McEwan Foundation. GH has received speaker's fees or consultancy fees from Nutricia and 4D Pharma
- Journal Article